1. Home
  2. KPLT vs EQ Comparison

KPLT vs EQ Comparison

Compare KPLT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Katapult Holdings Inc.

KPLT

Katapult Holdings Inc.

HOLD

Current Price

$7.36

Market Cap

52.2M

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.27

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KPLT
EQ
Founded
2012
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.2M
57.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
KPLT
EQ
Price
$7.36
$1.27
Analyst Decision
Hold
Hold
Analyst Count
1
1
Target Price
$10.00
$1.00
AVG Volume (30 Days)
1.1M
510.3K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$280,839,000.00
$4,392,000.00
Revenue This Year
$21.42
N/A
Revenue Next Year
$15.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.15
N/A
52 Week Low
$5.08
$0.27
52 Week High
$24.34
$2.35

Technical Indicators

Market Signals
Indicator
KPLT
EQ
Relative Strength Index (RSI) 46.74 62.36
Support Level $6.00 $0.84
Resistance Level $7.00 $1.44
Average True Range (ATR) 0.58 0.12
MACD 0.31 0.06
Stochastic Oscillator 35.88 74.52

Price Performance

Historical Comparison
KPLT
EQ

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: